Evaluation Of Vision Recovery And Comfort Index In Patients With Borderline/Mild Dry Eyes Undergoing FLACS With Premium IOL

Phase 4

• Conditions: Dry Eye Syndromes
• Interventions: Drug: Dextenza 0.4Mg Ophthalmic Insert; Drug: Prednisolone Acetate

• Registration Number: NCT04863742
• Lead Sponsor: Sight Medical Doctors PLLC

Brief Summary

This is a prospective, open-label, single-center, randomized, head-to-head, investigator-sponsored clinical study. It aims to investigate the vision recovery and patient comfort in borderline/mild dry eye disease patients undergoing FLACS with Premium PCIOL (i.e., Panoptix, Toric IOL (spherical/multifocal), ReStor, Symfony), receiving a 0.4mg dexamethasone intracanalicular insert when compared to patients receiving standard of care prednisolone acetate 1%.

Detailed Description

This is a prospective, open-label, single-center, randomized, head-to-head, investigator-sponsored clinical study. It aims to investigate the vision recovery and patient comfort in borderline/mild dry eye disease patients undergoing FLACS with Premium PCIOL (i.e., Panoptix, Toric IOL (spherical/multifocal), ReStor, Symfony), receiving a 0.4mg dexamethasone intracanalicular insert when compared to patients receiving standard of care prednisolone acetate 1%. After screening a given patient for inclusion and exclusion criteria, and gaining informed consent, a total of 30 patients will be randomized into two groups:

Group 1: 15 patients will undergo bilateral FLACS + Premium PCIOL in separate days and will receive a 0.4mg dexamethasone intracanalicular insert at the days of each surgery.

Group 2: 15 patients will undergo bilateral FLACS + Premium PCIOL in separate days and will receive prednisolone acetate 1% QID/ 1 week, TID/ 1 week, BID/1 week, QD/ 1 week regimen starting at the days of each surgery.

All patient eyes will receive Prolensa 0.07% ophthalmic solution QD for 4 weeks starting 3 days prior to surgery and Besivance 0.6% eye drops TID/starting 3 days prior to surgery.

Per enrolled eye, the study period will last for approximately 30 days after surgery, consisting of three postop follow-up visits (six total postop visits per patient). At Day 1, Day 7 and Day 30, primary and secondary endpoints will be assessed alongside standard-of-care procedures. SPEED questionnaire will be assessed by a masked survey administrator. Adjusting for enrollment period, the study will last a total of approximately 12 months, including submission for publication/ presentation.

Study Timeline

• Status Verified: 2021-04
• Study First Submitted: 2021-04-22
• Study Start: 2021-04-26
• Study First Submitted QC: 2021-04-26
• Last Update Submitted: 2021-04-26
• Study First Posted: 2021-04-28
• Last Update Posted: 2021-04-28
• Primary Completion: 2021-07-31
• Study Completion: 2021-09-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1. Demonstrate objective signs of Boderline/ Mild Ocular Surface Disease (OSD) [defined as mild symptoms, mild conjunctival staining (<2+ Superficial Punctate Keratitis), Tear Break-up Time <12s] or demonstrate symptoms of OSD determined by SPEED questionnaire (SPEED Score <10).
2. Nucleus sclerosis up to 2+ planning to undergo FLACS + Premium PCIOL in both eyes.
3. Ability to provide informed consent for procedures
4. Ability to attend scheduled follow up visits
5. No other corneal pathology to create unknown variability

Read More

Exclusion Criteria

1. Age less than 18
2. Pregnancy/currently breast-feeding
3. Inability to provide informed consent
4. Documented adverse reaction to steroid (e.g. "steroid responder", allergy, etc)
5. Punctal stenosis
6. Previous corneal transplant surgery or refractive surgery
7. Concurrent use of topical steroid eye drops
8. Systemic, topical or intravitreal steroid use within 1 month of baseline
9. Active history of chronic or recurrent inflammatory eye disease in either eye
10. History of ocular herpetic infection (inclusive of Herpes Simplex 1/2, Varicella Zoster, Epstein Barr, Cytomegalovirus)
11. History of neurotrophic keratitis, uncontrolled diabetes, or other disease entities that may preclude proper healing
12. Diagnosis of Glaucoma or use of topical glaucoma drops
13. Participation in other studies in the last 6 months

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Dextenza Arm	Dextenza 0.4Mg Ophthalmic Insert	-
Prednisolone Acetate 1%	Prednisolone Acetate	-

Primary Outcome Measures

Name	Time	Method
Mean change in Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA)	Baseline, Post-Operative Day 7 and Day 30	As measured by Best Corrected Visual Acuity (BCVA) from baseline and at 1 week and 30 days after surgery
Mean change in uncorrected Visual Acuity (VA)	Baseline, Post-Operative Day 7 and Day 30	As measured by uncorrected VA from baseline and at 1 week and 30 days after surgery
Mean change from baseline in Standardized Patient Evaluation of Eye Dryness (SPEED) score	Baseline, Post-Operative Day 7 and Day 30	As measured by SPEED score from baseline and at 1 week and 30 days after surgery

Secondary Outcome Measures

Name	Time	Method
Patient satisfaction with vision at 1 week and 30 days after surgery	Post-Operative Day 7 and Day 30	As measured by patient satisfaction survey
Mean change in corneal staining	Baseline and at POD 7 and POD 30	As measured by corneal staining
Mean change from baseline in (Central Subfield Thickness) CST	Post-Operative Day 7 and 30	As measured by CST
Mean number of artificial tear drops dosed per day	30 Day tear log.	As measured by patient daily log.
Mean change in tear break-up time (TBUT)	Baseline and at POD 7 and POD 30	As measured by TBUT
Mean change in tear osmolarity	Baseline and at POD 7 and POD 30	As measured by tear osmolarity

Trial Locations

Locations (1)

SightMD, LIASC; 🇺🇸 Brentwood, New York, United States